Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Effect of syringe-filling technique and risk for endophthalmitis after intravitreal injection of anti-VEGF agents
2 August 2022
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Aflibercept, Anti-vascular endothelial growth factor, Bevacizumab, Endophthalmitis, Filling, Prefilled syringe, Ranibizumab, Syringe
In this retrospective study the authors compare the risk for post-injection endophthalmitis between different anti-vascular endothelial growth factor (VEGF) agents and syringe preparation technique. This multicentre study included 197,402 injections. The drugs included in this study were three Anti-VEGF agents...
Wet AMD outcomes post cataract surgery
3 June 2021
| Kareem Waleed Alsaffarini
|
EYE - Cataract, EYE - Refractive
|
age-related cataract, antivascular endothelial growth factor, cataract surgery, wet age-related macular degeneration
The authors present the findings of a retrospective study looking at the progression of wet age-related macular degeneration (AMD) in patients who underwent cataract surgery. They recruited a series of 111 patients of which 38 were men and 73 were...
